Save up -80% on Efmoroctocog alfa
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Eloctate
|$556.70||1 kit (single dose) 250iu|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Eloctate coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Efmoroctocog alfa every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Efmoroctocog alfa volume of distribution
Following a single intravenous dose of 50 IU/kg in previously-treated adult patients with severe haemophilia A, mean volume of distribution at steady state (Vss) ranged from 49.1 to 52.6 mL/kg. Mean Vss in adolescent patients 12 to 18 years of age ranged from 57.6 to 59.4mL/kg. Mean Vss in pediatric patients < 12 years of age ranged from 49.5 to 63.1 mL/kg.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Efmoroctocog alfa
Efmoroctocog alfa is a long-acting, fully-recombinant factor VIII Fc fusion protein.
Efmoroctocog alfa mechanism of action
Factor VIII exists in a circulating protein complex consisting of two molecules via a non-covalent binding interaction; Factor VIII and von Willebrand factor. This complex remains inactive until the coagulation cascade is initiated, which activated factor VIII. Factor VIII is released from the protein complex upon activation and acts as a cofactor for factor IX-mediated conversion of factor X to activated factor X on phospholipid surfaces.
Dosage forms of Efmoroctocog alfa
|Eloctate||250iu||1 kit (single dose)||$547|
Antihemophilic Factor (Recombinant BDD), FC Fusion Protein Antihemophilic factor (recombinant, FC fusion protein)
Biogen Canada Inc
Indication of Efmoroctocog alfa
For the treatment of Haemophilia A.
Toxicity of Efmoroctocog alfa
Based on the findings from acute and repeated dose toxicity studies, efmoroctocog alfa displays no special hazard for humans. Studies to assess the genotoxicity, carcinogenicity, toxicity to reproduction or embryo-foetal development of efmoroctocog alfa have not been conducted. In a placental transfer study, efmoroctocog alfa has been shown to cross the placenta in small amounts in mice.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Efmoroctocog alfa on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.